Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Points To Pipeline Depth Beyond Oncology

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

At a late-stage pipeline review, Roche execs stressed the advances being made outside the company’s specialty focus on oncology, including neuroscience, inflammation and ophthalmology.

You may also be interested in...



Roche's Dry AMD Drug Lampalizumab Delivers Disappointment In Phase III

Analysts had already been doubtful about the prospects for success in the Spectri study. A second Phase III trial is ongoing, but the candidate is already being removed from revenue models.

Ophthalmology M&A Engine Keeps Roaring As Akorn Buys Out Hi-Tech

CEO Raj Rai calls the transaction a “transformative event” for Akorn that will be instantly accretive and produce between $15 million and $20 million of run-rate synergies within 12 months. Acquisition of Hi-Tech adds prescription and OTC products, 18 filed ANDAs and increased manufacturing capability.

Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback

Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS005245

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel